Pipeline

Aduro’s extensive pipeline of diverse product candidates builds from proprietary technologies (STING Pathway Activators and B-select monoclonal antibodies) to create immunotherapies targeting a variety of cancers, as well as infectious and autoimmune diseases.

STING Pathway Programs

ADU-S100 (MIW815)

Multiple tumors
 
     

ADU-S100 (MIW815)

Multiple tumors
spartalizumab
     

ADU-S100 (MIW815)

Melanoma
ipilimumab
     

ADU-S100 (MIW815)

Head & Neck Cancer
anti-PD-1
     

cGAS-STING Inhibitors

Autoimmune
/inflammatory diseases
 
     
Indication
Combination

APRIL Pathway Programs

BION-1301

Multiple Myeloma
 
     

BION-1301

IgA Nephropathy
 
     
Indication
Combination

Additional Partnered Programs

Anti-CD27 agonist

Oncology
 
     
Indication
Combination